CHANGCHUN, Jilin, CHINA, 10 November 2026 — A new peer-reviewed review in Psychedelics opens on a strange fact, gathered from existing laboratory studies rather than new experiments: a brain tumor can learn to eavesdrop.
In experimental models, glioma cells slip into neuronal networks and form working, synapse-like contacts with the neurons around them, drawing on glutamate signaling and on factors such as neuroligin-3 and BDNF that neurons release when they are active. One study the authors cite gave the phenomenon a name that reads like a diagnosis in itself: malignant synaptic plasticity. Tumors elsewhere in the body do something similar with wiring. Cancers of the prostate, breast, and pancreas are often threaded with autonomic and sensory nerves, and in prostate cancer, sympathetic nerve infiltration has been linked to tumor proliferation through norepinephrine and beta-adrenergic signaling.
That is the puzzle behind the review, written by Feilong Cheng, Dr. Cong Lin, and Professor Xiaohui Wang of the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, together with Professor Shanwen Chen of the Department of Gastrointestinal Surgery at Peking University First Hospital. If cancer has learned to use the nervous system, could drugs that profoundly reshape the nervous system push back? The honest answer, the authors argue, is that nobody yet knows. They say so with unusual persistence.
A map with the strata labeled
This is a narrative review, explicitly framed as hypothesis-generating; it is neither a new experiment nor a formal systematic review. The team ran a targeted literature survey of PubMed/MEDLINE, Web of Science, and Google Scholar, covering January 2000 through December 2025, and gave priority to randomized and controlled trials in cancer and palliative settings alongside recent high-impact mechanistic work. The paper does not report a total count of included studies or a formal quality or risk-of-bias score.
Then the authors imposed a discipline on themselves. Every claim is sorted into one of four tiers: clinically supported, human-mixed, preclinical, or hypothesis. The effect resembles a geological core sample with each layer tagged, so that no reader mistakes bedrock for loose sediment.
Bedrock: the fear, not the tumor
The firmest layer is not about tumors at all. It is about dread. Advanced cancer brings death anxiety, loss of meaning, demoralization, and spiritual suffering, which the review notes are often incompletely addressed by conventional drugs and psychotherapy. Randomized controlled trials published in 2016, which the review treats as its strongest human evidence, reported rapid and sustained reductions in cancer-related anxiety, depression, and existential distress after one or two supervised high-dose psilocybin sessions embedded in structured preparation and integration. Patients also described a renewed sense of meaning, acceptance, and connectedness.
The benefit, the authors stress, belongs to the drug and the setting together. Why might a single supervised session leave a lasting mark? Neuroimaging studies summarized in the review show that psychedelics loosen the internal integrity of the default mode network, circuitry associated with self-referential thought and rumination, while increasing connectivity between networks. The authors treat this as a correlational account, drawn largely from psychiatric and healthy-volunteer samples, and not as proof of how relief happens in people with cancer.
Pain, opioids, and a refusal to oversell
Pain is where enthusiasm tends to run ahead of data, and the review declines to follow it. The evidence here is preliminary and heterogeneous, resting largely on early case series, chronic pain studies, and healthy volunteers. In one experimental paradigm, low, sub-hallucinogenic doses of LSD increased tolerance to cold pressor pain and reduced ratings of pain unpleasantness. Does that translate to the pain of advanced cancer? Not yet established.
The authors write that claims of reduced opioid requirements, or of psychedelics broadly outperforming standard analgesics, are not supported by robust oncology trials. Psychedelics are not typically associated with opioid-type respiratory depression, yet the review resists calling them uniformly “safer,” since they carry their own risks, including acute anxiety and cardiovascular effects.
Sediment: the immune hypotheses
Below the clinical bedrock, the ground softens. Some clinical reports describe drops in the inflammatory markers IL-6 and TNF-alpha after psilocybin, but magnitude, durability, and reproducibility remain unestablished, and protocols vary. In laboratory systems, the serotonin 5-HT2A receptor, the principal target of classic psychedelics, appears on subsets of lymphocytes and macrophage-lineage cells, and its activation has been linked to lower pro-inflammatory cytokines. Chronic inflammation is a recognized feature of many malignancies. It is tempting to draw a straight line from one fact to the other. The authors decline.
The most suggestive thread comes from mice. In tumor-bearing animals, experimentally activating reward-related dopaminergic circuitry reduced sympathetic signaling, altered the mobilization of immunoregulatory cells from bone marrow, and slowed tumor growth in that model. Could a profound positive emotional experience in a human engage something similar? The review calls it plausible and unproven, in that order. And what would it take to show that a change in mood reaches a tumor at all?
Where the evidence argues with itself
Here the synthesis turns genuinely interesting, because the findings pull in opposite directions. Some preclinical studies reported accelerated tumor growth when psychedelics were given alone, under certain model- and dose-dependent conditions. Other experimental work found that pairing a psychedelic with immune checkpoint inhibitors coincided with better antitumor responses than checkpoint blockade alone, a result the authors say requires independent replication. Large epidemiological analyses, meanwhile, generally reported no significant association between lifetime psychedelic use and overall cancer incidence, though observational designs cannot establish causality.
There is a further twist for anyone picturing psychedelics as simple anti-inflammatories. A shift toward mediators such as IL-10 or TGF-beta could, in some contexts, dampen antitumor immune surveillance and might interact with concurrent immunotherapy. Is calming inflammation always good news for a person with cancer? The review suggests the answer depends on context, and that the clinical data needed to settle it are sparse.
The work still ahead
The authors are plain that current evidence does not support routine incorporation of psychedelics into standard cancer treatment. Tumor-related and survival endpoints remain largely untested. The safety questions are concrete: transient rises in blood pressure and heart rate, possible arrhythmia risk in susceptible individuals, and heightened caution for patients with brain tumors or brain metastases because of seizure risk and intracranial pressure. Which patients should never be offered a session? Screening for personal or family history of psychosis or bipolar disorder is one starting point, and drug-drug interaction studies remain needed.
Their proposed path is staged rather than heroic: trials that pre-specify psychological and quality-of-life endpoints while collecting exploratory biomarkers; safety-first studies in patients receiving immunotherapy; survivorship studies on neuropathic pain, fatigue, and sleep; and animal tumor models designed to separate stress physiology from direct neuroimmune effects. Further out sits a provocative question. Could “psychoplastogens,” compounds that promote neuroplasticity with reduced or absent subjective effects, make treatment feasible for medically fragile patients? That, too, the authors label hypothesis-generating.
A smaller, more humane claim
Near the end, the authors write that the near-term goal is not “mystical cures” but scientifically testable, ethically delivered interventions that improve quality of life. It is a smaller claim than the ones psychedelics usually attract, and a more useful one. Cancer-related suffering, as the review frames it, unfolds in a brain-body context where stress physiology, immune signaling, and meaning-related distress interact. Whether easing the fear can ever reach the tumor is a question the field has only begun to ask with proper rigor. The relief, for selected patients in carefully supported settings, is already on the record.
The work was supported by the National Natural Science Foundation of China, the STI2030-Major Projects, the International Partnership Program of the Chinese Academy of Sciences, and the Jilin Province Science and Technology Program. The authors declare no conflict of interest.
The peer-reviewed review in Psychedelics titled “Exploring cancer neuroscience with psychedelics: Brain-body crosstalk, neuroimmune modulation, and implications from tumor biology to end-of-life support,” is freely available via Open Access, starting on 10 November 2026 in Psychedelics at the following hyperlink: https://doi.org/10.61373/pp026w.0009
The full reference for citation purposes is: Cheng F, Lin C, Chen S, Wang X. Exploring cancer neuroscience with psychedelics: Brain-body crosstalk, neuroimmune modulation, and implications from tumor biology to end-of-life support. Psychedelics 2026. DOI: https://doi.org/10.61373/pp026w.0009 . Epub 2026 Nov 10.
About Psychedelics: Psychedelics: The Journal of Psychedelic and Psychoactive Drug Research (ISSN: 2997-2671, online and 2997-268X, print) is a peer reviewed medical research journal published by Genomic Press, New York. Psychedelics is dedicated to advancing knowledge across the full spectrum of consciousness altering substances, from classical psychedelics to stimulants, cannabinoids, entactogens, dissociatives, plant derived compounds, and novel compounds including drug discovery approaches. Our multidisciplinary approach encompasses molecular mechanisms, therapeutic applications, neuroscientific discoveries, and sociocultural analyses. We welcome diverse methodologies and perspectives from fundamental pharmacology and clinical studies to psychological investigations and societal-historical contexts that enhance our understanding of how these substances interact with human biology, psychology, and society.
Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/
Our media website is at: https://media.genomicpress.com/
Our full website is at: https://genomicpress.com/
Psychedelics
Literature review
People
Exploring cancer neuroscience with psychedelics: Brain-body crosstalk, neuroimmune modulation, and implications from tumor biology to end-of-life support
10-Nov-2026
The authors declare no conflict of interest.